Geriatrics

Investigators examined anti-VEGF injections claims data among Medicare Part B beneficiaries from 2012 to 2015 and found that aflibercept injections increased by 69% during that time.

A recent study reviewed operating times of ophthalmic procedures before and after transition to a new EHR system in 2 outpatient departments and an ambulatory surgical center.

A study presented at ADA 2019 examined the efficacy of sitagliptin compared with dapagliflozin in t2d patients 65 years old and older.

A three-arm clinical trial of the SAMBA program showed that screening for and tailoring to individuals' asthma needs improves their condition management.

Ranibizumab was approved for AMD treatment in Korea in 2007, but most supporting trials had been conducted among Caucasian patients.

A review highlights aflibercept’s efficacy in treatment non-responders and points to a couple promising new AMD therapies in development.

Metformin use associated with a 58% reduced risk of age-related macular degeneration (AMD) in a case-controlled retrospective study.

The field has a growing demand of care, and dropping rate of new specialists. The solution can start at medical schools.

Jason Hsu, MD, and his colleagues at the Wills Eye Hospital presented a study at ARVO 2019 regarding short-term outcomes of patients, with nAMD, who switched from afliberecept to ranibizumab.

Investigators examined more than 600 fellow eyes in a secondary analysis to identify 2 imaging features and 1 genetic variant linked to conversion.

In a 15-year study, investigators found that moderate consumption of eggs can significantly reduce a patient’s risk of developing incident, late-stage age related-macular degeneration

After a Mendelian analysis, investigators found that the genetic variants examined explained 4.4% of the variance in refractive error in their patient sample.

The humanized single-chain antibody fragment could become the first of its kind approved for the common eye condition.

Study finds that patients who received as-needed injections saw a significant anatomical and functional improvement.

Investigators found that intravitreal administration of aflibercept might alter the corneal endothelium within 6 months of their first injection.

The best way to diagnose diabetic macular edema is using optical coherence tomography, but it is costly.

More than 80% of patients saw maintenance or improvement of BCVA, with a mean improvment of 7 letters or more, according to the ETDRS system.

Though it has been shown to not be harmful to patients at risk for the opitcal condition, calcium may still play a protective role in these patients.

Investigators from Johns Hopkins examined 16 RCTs to determine efficacy of three anti-VEGF agents for patients with neovascular age-related macular degeneration.

While the diseases appear to be unrelated, there may be underlying factors that link them together.

There has been a debate about whether retina specialists under-treat with anti-VEGF therapy in the real-world setting.

Investigators found an association between disease progression change in done dark adaptation, yellow-blue, chromatic threshold and foveal thickness.

The loteprednol etabonate ophthalmic gel 0.38% was proven efficacious and safe in a pair of double-masked trials, and will reach the market by April 2019.

The investigators also examined patients who had 3 or more injections in the year prior to their cardiac event.

FDA trial approval would make this trial the first ever to test a stem cell-based therapy derived from induced pluripotent stem cells for treating any disease.

A new analysis of an ongoing clinical study offers insights for treating retinal vein occlusion in poor responders to bevacizumab.

Pigment epithelial detachment is less responsive to anti-VEGF treatment, compared to subretinal fluid or intraretinal cysts in nAMD, investigators observed.

Hepatitis B virus may also accelerate the progression of the optical disease, according to investigators.

New PANORAMA phase 3 trial results add to the anti-VEGF's profile for treatment of diabetic retinopathy.

Patients administered either anti-VEGF therapy for nAMD tested similar for improved visual acuity over an observed 12-month treatment period.